Gene:
CYP3A4
cytochrome P450, family 3, subfamily A, polypeptide 4


Annotated Labels

  1. Annotation of FDA Label for enzalutamide and CYP2C19,CYP2C8,CYP2C9,CYP3A4
  2. Annotation of EMA Label for aripiprazole and CYP2D6,CYP3A4
  3. Annotation of EMA Label for cabazitaxel and CYP3A4
  4. Annotation of EMA Label for darunavir and CYP3A4
  5. Annotation of EMA Label for dronedarone and CYP2D6,CYP3A4
  6. Annotation of EMA Label for fosamprenavir and CYP3A4
  7. Annotation of EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR
  8. Annotation of EMA Label for indinavir and CYP3A4
  9. Annotation of EMA Label for ivabradine and CYP3A4
  10. Annotation of EMA Label for nelfinavir and CYP3A4
  11. Annotation of EMA Label for posaconazole and CYP3A4
  12. Annotation of EMA Label for ritonavir and CYP2D6,CYP3A4
  13. Annotation of EMA Label for ruxolitinib and CYP3A4
  14. Annotation of EMA Label for sirolimus and CYP3A4
  15. Annotation of EMA Label for sunitinib and CYP3A4
  16. Annotation of EMA Label for telithromycin and CYP3A4
  17. Annotation of EMA Label for tipranavir and CYP3A4
  18. Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4
  19. Annotation of EMA Label for zonisamide and CYP3A4


last updated 10/25/2013

2. Annotation of EMA Label for aripiprazole and CYP2D6,CYP3A4

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) recommends dose adjustments when aripiprazole is taken with CYP3A4 inhibitors in CYP2D6 poor metabolizers, or concomitant use of CYP3A4 or CYP2D6 inhibitors, or CYP3A4 inducers.

There's more of this label. Read more.


last updated 08/21/2014

3. Annotation of EMA Label for cabazitaxel and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for cabazitaxel (Jevtana) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A, and coadministration of strong CYP3A inhibitors or inducers should be avoided.

There's more of this label. Read more.


last updated 09/17/2014

4. Annotation of EMA Label for darunavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.

There's more of this label. Read more.


last updated 09/16/2014

5. Annotation of EMA Label for dronedarone and CYP2D6,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.

There's more of this label. Read more.


last updated 09/16/2014

6. Annotation of EMA Label for fosamprenavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for fosamprenavir (Telzir) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. Concomitant use of drugs with a narrow therapeutic window that are substrates of CYP3A4 or CYP2D6 is contraindicated.

There's more of this label. Read more.


last updated 10/25/2013

7. Annotation of EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR

Testing required

Summary

The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of gefitinib (Iressa) in patients with tumors that have activating EGFR mutations, due to its mechanism of action.

There's more of this label. Read more.


last updated 09/16/2014

8. Annotation of EMA Label for indinavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for indinavir (Crixivan) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contraindicates concomitant use of drugs that are CYP3A4 substrates.

There's more of this label. Read more.


last updated 09/16/2014

9. Annotation of EMA Label for ivabradine and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ivabradine (Corlentor) does not contain pharmacogenetic information. It contains information regarding metabolism of ivabradine by CYP3A4, and that concomitant use of potent CYP3A4 inhibitors is contraindicated.

There's more of this label. Read more.


last updated 10/27/2013

10. Annotation of EMA Label for nelfinavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for nelfinavir (Viracept) contains information regarding the metabolism of the drug by CYP3A4, CYP2C19 and CYP2D6, and that concomitant use of CYP3A4 substrates or inducers is contraindicated. No genetic information is included.

There's more of this label. Read more.


last updated 09/16/2014

11. Annotation of EMA Label for posaconazole and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for posaconazole (Noxafil) does not contain pharmacogenetic information. It contains information regarding metabolism drug-drug interactions with CYP3A4 substrates.

There's more of this label. Read more.


last updated 09/15/2014

12. Annotation of EMA Label for ritonavir and CYP2D6,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.

There's more of this label. Read more.


last updated 09/12/2014

13. Annotation of EMA Label for ruxolitinib and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for ruxolitinib (Jakavi) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and CYP2C9, and suggests dosing adjustments and more frequent monitoring of hematology parameters if co-administered with strong CYP3A4 inhibitors or inducers, or dual inhibitors of CYP3A4 and CYP2C9.

There's more of this label. Read more.


last updated 09/15/2014

14. Annotation of EMA Label for sirolimus and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for sirolimus (Rapamune) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends therapeutic monitoring and dose adjustments when coadministrated with strong CYP3A inhibitors or inducers.

There's more of this label. Read more.


last updated 09/16/2014

15. Annotation of EMA Label for sunitinib and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.

There's more of this label. Read more.


last updated 09/16/2014

16. Annotation of EMA Label for telithromycin and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for telithromycin (Ketek) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contains information regarding use of concomitant drugs that are CYP3A4 substrates, inhibitors or inducers.

There's more of this label. Read more.


last updated 09/17/2014

17. Annotation of EMA Label for tipranavir and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for tipranavir (Aptivus) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of tipranavir by CYP3A4, and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.

There's more of this label. Read more.


last updated 08/06/2014

18. Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

There's more of this label. Read more.


last updated 09/16/2014

19. Annotation of EMA Label for zonisamide and CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for zonisamide (Zonegran) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends dose adjustments if CYP3A4 inducers are taken concomitantly.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for CYP3A4

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1 N/A N/A N/A
No VIP available No VIP available VA *1A N/A N/A N/A
No VIP available No VIP available VA *1B N/A N/A N/A
No VIP available CA VA *1G N/A N/A N/A
No VIP available No VIP available VA *2 N/A N/A N/A
No VIP available No VIP available VA *3 N/A N/A N/A
No VIP available CA VA *4 N/A N/A N/A
No VIP available No VIP available VA *7 N/A N/A N/A
No VIP available CA VA *8 N/A N/A N/A
No VIP available No VIP available VA *9 N/A N/A N/A
No VIP available No VIP available VA *11 N/A N/A N/A
No VIP available No VIP available VA *12 N/A N/A N/A
No VIP available No VIP available VA *18 N/A N/A N/A
No VIP available No VIP available VA *18B N/A N/A N/A
No VIP available CA VA *20 N/A N/A N/A
No VIP available CA VA *22 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs12333983 NC_000007.13:g.99354114T>A, NC_000007.14:g.99756491T>A, NG_008421.1:g.32695A>T, NM_001202855.2:c.*1642A>T, NM_017460.5:c.*1642A>T, XM_011515841.1:c.*1642A>T, XM_011515842.1:c.*1642A>T, rs61591143
T > A
SNP
rs12721627 NC_000007.13:g.99366093G>C, NC_000007.14:g.99768470G>C, NG_008421.1:g.20716C>G, NM_001202855.2:c.554C>G, NM_017460.5:c.554C>G, NP_001189784.1:p.Thr185Ser, NP_059488.2:p.Thr185Ser, XM_011515841.1:c.554C>G, XM_011515842.1:c.554C>G, XP_011514143.1:p.Thr185Ser, XP_011514144.1:p.Thr185Ser, rs28371754, rs56915287
G > C
SNP
T185S
rs12721634 NC_000007.13:g.99381661A>G, NC_000007.14:g.99784038A>G, NG_008421.1:g.5148T>C, NM_001202855.2:c.44T>C, NM_017460.5:c.44T>C, NP_001189784.1:p.Leu15Pro, NP_059488.2:p.Leu15Pro, XM_011515841.1:c.44T>C, XM_011515842.1:c.44T>C, XP_011514143.1:p.Leu15Pro, XP_011514144.1:p.Leu15Pro, rs386525810
A > G
SNP
L15P
No VIP available No Clinical Annotations available VA
rs1851426 NC_000007.13:g.99382936A>G, NC_000007.14:g.99785313A>G, NG_008421.1:g.3873T>C, NM_001202855.2:c.-1232T>C, NM_017460.5:c.-1232T>C, XM_011515841.1:c.-1232T>C, XM_011515842.1:c.-1232T>C, rs56476282, rs57950778
A > G
SNP
No VIP available CA VA
rs2242480 NC_000007.13:g.99361466C>T, NC_000007.14:g.99763843C>T, NG_008421.1:g.25343G>A, NM_001202855.2:c.1023+12G>A, NM_017460.5:c.1026+12G>A, XM_011515841.1:c.1026+12G>A, XM_011515842.1:c.1023+12G>A, rs10364667, rs12721630, rs17161804, rs28969389, rs59491337, rs72494459, rs9655766
C > T
SNP
No VIP available CA VA
rs2246709 NC_000007.13:g.99365719A>G, NC_000007.14:g.99768096A>G, NG_008421.1:g.21090T>C, NM_001202855.2:c.670+258T>C, NM_017460.5:c.670+258T>C, XM_011515841.1:c.670+258T>C, XM_011515842.1:c.670+258T>C, rs56901335
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2687116 NC_000007.13:g.99365943C>A, NC_000007.14:g.99768320C>A, NG_008421.1:g.20866G>T, NM_001202855.2:c.670+34G>T, NM_017460.5:c.670+34G>T, XM_011515841.1:c.670+34G>T, XM_011515842.1:c.670+34G>T, rs17161901, rs59381366
C > A
SNP
rs2740574 NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892
C > T
SNP
No VIP available CA VA
rs28371759 NC_000007.13:g.99361626A>G, NC_000007.14:g.99764003A>G, NG_008421.1:g.25183T>C, NM_001202855.2:c.875T>C, NM_017460.5:c.878T>C, NP_001189784.1:p.Leu292Pro, NP_059488.2:p.Leu293Pro, XM_011515841.1:c.878T>C, XM_011515842.1:c.875T>C, XP_011514143.1:p.Leu293Pro, XP_011514144.1:p.Leu292Pro, rs386574775, rs60608883
A > G
SNP
L292P
No VIP available CA VA
rs35599367 NC_000007.13:g.99366316G>A, NC_000007.14:g.99768693G>A, NG_008421.1:g.20493C>T, NM_001202855.2:c.522-191C>T, NM_017460.5:c.522-191C>T, XM_011515841.1:c.522-191C>T, XM_011515842.1:c.522-191C>T, rs45581939, rs62471940
G > A
SNP
No VIP available CA VA
rs3735451 NC_000007.13:g.99355975T>C, NC_000007.14:g.99758352T>C, NG_008421.1:g.30834A>G, NM_001202855.2:c.1414-124A>G, NM_017460.5:c.1417-124A>G, XM_011515841.1:c.1510-124A>G, XM_011515842.1:c.1507-124A>G, rs386585004, rs57555923
T > C
SNP
No VIP available CA VA
rs4646437 NC_000007.13:g.99365083G>A, NC_000007.14:g.99767460G>A, NG_008421.1:g.21726C>T, NM_001202855.2:c.671-205C>T, NM_017460.5:c.671-202C>T, XM_011515841.1:c.671-202C>T, XM_011515842.1:c.671-205C>T, rs386594232, rs57997883
G > A
SNP
No VIP available CA VA
rs4646440 NC_000007.13:g.99360870G>A, NC_000007.14:g.99763247G>A, NG_008421.1:g.25939C>T, NM_001202855.2:c.1023+608C>T, NM_017460.5:c.1026+608C>T, XM_011515841.1:c.1026+608C>T, XM_011515842.1:c.1023+608C>T, rs386594233, rs56791612
G > A
SNP
rs4986907 NC_000007.13:g.99367427C>T, NC_000007.14:g.99769804C>T, NG_008421.1:g.19382G>A, NM_001202855.2:c.485G>A, NM_017460.5:c.485G>A, NP_001189784.1:p.Arg162Gln, NP_059488.2:p.Arg162Gln, XM_011515841.1:c.485G>A, XM_011515842.1:c.485G>A, XP_011514143.1:p.Arg162Gln, XP_011514144.1:p.Arg162Gln, rs58254554
C > T
SNP
R162Q
rs4986908 NC_000007.13:g.99367392C>T, NC_000007.14:g.99769769C>T, NG_008421.1:g.19417G>A, NM_001202855.2:c.520G>A, NM_017460.5:c.520G>A, NP_001189784.1:p.Asp174Asn, NP_059488.2:p.Asp174Asn, XM_011515841.1:c.520G>A, XM_011515842.1:c.520G>A, XP_011514143.1:p.Asp174Asn, XP_011514144.1:p.Asp174Asn, rs386597003, rs58133974
C > T
SNP
D174N
rs4986909 NC_000007.13:g.99359670G>A, NC_000007.14:g.99762047G>A, NG_008421.1:g.27139C>T, NM_001202855.2:c.1244C>T, NM_017460.5:c.1247C>T, NP_001189784.1:p.Pro415Leu, NP_059488.2:p.Pro416Leu, XM_011515841.1:c.1247C>T, XM_011515842.1:c.1244C>T, XP_011514143.1:p.Pro416Leu, XP_011514144.1:p.Pro415Leu, rs386597004
G > A
SNP
P415L
rs4986910 NC_000007.13:g.99358524A>G, NC_000007.14:g.99760901A>G, NG_008421.1:g.28285T>C, NM_001202855.2:c.1331T>C, NM_017460.5:c.1334T>C, NP_001189784.1:p.Met444Thr, NP_059488.2:p.Met445Thr, XM_011515841.1:c.1427T>C, XM_011515842.1:c.1424T>C, XP_011514143.1:p.Met476Thr, XP_011514144.1:p.Met475Thr, rs386597005, rs60835115
A > G
SNP
M444T
rs4986913 NC_000007.13:g.99358459G>A, NC_000007.14:g.99760836G>A, NG_008421.1:g.28350C>T, NM_001202855.2:c.1396C>T, NM_017460.5:c.1399C>T, NP_001189784.1:p.Pro466Ser, NP_059488.2:p.Pro467Ser, XM_011515841.1:c.1492C>T, XM_011515842.1:c.1489C>T, XP_011514143.1:p.Pro498Ser, XP_011514144.1:p.Pro497Ser, rs386597007
G > A
SNP
P466S
No VIP available No Clinical Annotations available VA
rs4986914 NC_000007.13:g.99382233A>G, NC_000007.14:g.99784610A>G, NG_008421.1:g.4576T>C, NM_001202855.2:c.-529T>C, NM_017460.5:c.-529T>C, XM_011515841.1:c.-529T>C, XM_011515842.1:c.-529T>C
A > G
SNP
rs4987161 NC_000007.13:g.99366081A>G, NC_000007.14:g.99768458A>G, NG_008421.1:g.20728T>C, NM_001202855.2:c.566T>C, NM_017460.5:c.566T>C, NP_001189784.1:p.Phe189Ser, NP_059488.2:p.Phe189Ser, XM_011515841.1:c.566T>C, XM_011515842.1:c.566T>C, XP_011514143.1:p.Phe189Ser, XP_011514144.1:p.Phe189Ser
A > G
SNP
F189S
No VIP available CA VA
rs56324128 NC_000007.13:g.99375702C>T, NC_000007.14:g.99778079C>T, NG_008421.1:g.11107G>A, NM_001202855.2:c.167G>A, NM_017460.5:c.167G>A, NP_001189784.1:p.Gly56Asp, NP_059488.2:p.Gly56Asp, XM_011515841.1:c.167G>A, XM_011515842.1:c.167G>A, XP_011514143.1:p.Gly56Asp, XP_011514144.1:p.Gly56Asp, rs386626576, rs59765626
C > T
SNP
G56D
No VIP available No Clinical Annotations available VA
rs6956344 NC_000007.13:g.99359151C>T, NC_000007.14:g.99761528C>T, NG_008421.1:g.27658G>A, NM_001202855.2:c.1250+513G>A, NM_017460.5:c.1253+513G>A, XM_011515841.1:c.1346+248G>A, XM_011515842.1:c.1343+248G>A
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  CYP3A3
Alternate Symbols:  None
PharmGKB Accession Id: PA130

Details

Cytogenetic Location: chr7 : q22.1 - q22.1
GP mRNA Boundary: chr7 : 99354583 - 99381811
GP Gene Boundary: chr7 : 99351583 - 99391811
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Note: The CYP3A4 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand; therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

CYP3A4 (cytochrome P450 3A4) encodes a member of the cytochrome P450 superfamily of enzymes. CYP3A4 and CYP3A5 are believed to be the predominant cytochrome P450s expressed in adult human liver, with CYP3A4 thought to dominate in Whites and CYP3A5 in Blacks/African Americans. The two have overlapping substrate specificities. CYP3A4 is responsible for the metabolism of approximately 50-60% of clinical drugs used today, including acetaminophen, codeine, cyclosporine A, diazepam, and erythromycin. It is important for the metabolism of steroid hormones [Articles:9667077, 9054608, 9187528, 3259858].

The complete cDNA sequence was reported by Molowa et al. in 1986 [Article:3460094], and Inoue et al. later mapped the gene to 7q22.1 by fluorescence in situ hybridization [Article:1391968]. The gene is about 27 kb in length and contains 13 exons and 12 introns [Article:8269949].

Linkage results from a Japanese population [Article:14695543] demonstrate that CYP3A4 and CYP3A5 haplotypes are closely linked and that the two genes are in the same gene block, so some effects originally thought to be due to a CYP3A4 allele are probably actually due to a CYP3A5 allele in linkage disequilibrium.

Though extensively studied, most of the CYP3A4 haplotypes have not been indisputably shown to affect expression or activity in terms of pharmacodynamics or pharmacokinetics. One recently discovered rare haplotype, CYP3A4*20, contains a premature stop codon which does result in a truncated protein and complete loss of function [Article:16580902]; this publication also contains excellent overview information for CYP3A4. This haplotype has been identified in only one family (of Brazilian origin) to date.

The g.82,266 (on AF280107 ) polymorphism (part of haplotypes *18B and *19 ) may contribute to variability in response to clopidogrel (which requires metabolism by CYP3A4 to be active). This study was done in a Spanish (White) population of coronary artery disease patients also being treated with aspirin [Article:16645157].
The *16B haplotype has been reported to result in altered paclitaxel metabolite levels in Japanese (Asian) cancer patients [Article:16890579]. One study showed that cancer patients carrying CYP3A4*1B may have a higher rate of docetaxel clearance and so a lower exposure to docetaxel [Article:16765145], though this actually may be due to the linked CYP3A5*1. However, Lewis et al. [Article:17545536] found no significant relationship between CYP3A4*1B and docetaxol clearance in African American (Black or African American) and Caucasian(White) cancer patients.

Chu et al. recently found that white female breast cancer patients who are CYP3A4 *1B carriers may have an increased risk of developing endometrial cancer after tamoxifen treatment when compared with non -*1B carriers [Article:17434921].

In vitro, CYP3A*1B has been reported to lead to increased transcription [Article:14673875], though there have been conflicting results as well [Article:14515058].

Also see Lamba et al. [Article:12406645], Lee and Goldstein[Article:16004554]http://www.imm.ki.se/cypalleles/cyp3a4.htm .

Citation
M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417. Full text
History

Submitted by Alan Shuldiner (PAPI), Michelle Whirl Carillo(PharmGKB), Joan M. Hebert(PharmGKB)

Key Publications
  1. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis. 2007. Chu William, Fyles Anthony, Sellers Edward M, McCready David R, Murphy Joan, Pal Tuya, Narod Steven A. PubMed
  2. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Lewis Lionel D, Miller Antonius A, Rosner Gary L, Dowell Jonathan E, Valdivieso Manuel, Relling Mary V, Egorin Merrill J, Bies Robert R, Hollis Donna R, Levine Ellis G, Otterson Gregory A, Millard Frederick, Ratain Mark J, Cancer and Leukemia Group B. PubMed
  3. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clinical pharmacology and therapeutics. 2006. Nakajima Yukiko, Yoshitani Takashi, Fukushima-Uesaka Hiromi, Saito Yoshiro, Kaniwa Nahoko, Kurose Kouichi, Ozawa Shogo, Aoyagi Nobuo, Kamatani Naoyuki, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Tamura Tomohide, Yoshida Teruhiko, Minami Hironobu, Saijo Nagahiro, Katori Noriko, Sawada Jun-ichi. PubMed
  4. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clinical pharmacology and therapeutics. 2006. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer J M. PubMed
  5. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arteriosclerosis, thrombosis, and vascular biology. 2006. Angiolillo Dominick J, Fernandez-Ortiz Antonio, Bernardo Esther, Ramírez Celia, Cavallari Ugo, Trabetti Elisabetta, Sabaté Manel, Hernández Rosana, Moreno Raul, Escaned Javier, Alfonso Fernando, Bañuelos Camino, Costa Marco A, Bass Theodore A, Pignatti Pier Franco, Macaya Carlos. PubMed
  6. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clinical pharmacology and therapeutics. 2006. Westlind-Johnsson Anna, Hermann Robert, Huennemeyer Andreas, Hauns Bernhard, Lahu Gezim, Nassr Nassr, Zech Karl, Ingelman-Sundberg Magnus, von Richter Oliver. PubMed
  7. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005. Lee Su-Jun, Goldstein Joyce A. PubMed
  8. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human mutation. 2004. Fukushima-Uesaka Hiromi, Saito Yoshiro, Watanabe Hidemi, Shiseki Kisho, Saeki Mayumi, Nakamura Takahiro, Kurose Kouichi, Sai Kimie, Komamura Kazuo, Ueno Kazuyuki, Kamakura Shiro, Kitakaze Masafumi, Hanai Sotaro, Nakajima Toshiharu, Matsumoto Kenji, Saito Hirohisa, Goto Yu-ichi, Kimura Hideo, Katoh Masaaki, Sugai Kenji, Minami Narihiro, Shirao Kuniaki, Tamura Tomohide, Yamamoto Noboru, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Kitamura Yutaka, Kamatani Naoyuki, Ozawa Shogo, Sawada Jun-ichi. PubMed
  9. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003. Floyd Michael D, Gervasini Guillermo, Masica Andrew L, Mayo Gail, George Alfred L, Bhat Kolari, Kim Richard B, Wilkinson Grant R. PubMed
  10. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environmental and molecular mutagenesis. 2003. Amirimani B, Ning B, Deitz A C, Weber B L, Kadlubar F F, Rebbeck T R. PubMed
  11. Genetic contribution to variable human CYP3A-mediated metabolism. Advanced drug delivery reviews. 2002. Lamba Jatinder K, Lin Yvonne S, Schuetz Erin G, Thummel Kenneth E. PubMed
  12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clinical pharmacology and therapeutics. 2000. Sata F, Sapone A, Elizondo G, Stocker P, Miller V P, Zheng W, Raunio H, Crespi C L, Gonzalez F J. PubMed
  13. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica; the fate of foreign compounds in biological systems. 1998. Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, Katagiri M. PubMed
  14. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis. 1997. Shou M, Korzekwa K R, Brooks E N, Krausz K W, Gonzalez F J, Gelboin H V. PubMed
  15. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug metabolism reviews. 1997. Rendic S, Di Carlo F J. PubMed
  16. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. European journal of biochemistry / FEBS. 1993. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T. PubMed
  17. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. The Japanese journal of human genetics. 1992. Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich F P, Abe T. PubMed
  18. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Archives of biochemistry and biophysics. 1988. Waxman D J, Attisano C, Guengerich F P, Lapenson D P. PubMed
  19. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proceedings of the National Academy of Sciences of the United States of America. 1986. Molowa D T, Schuetz E G, Wrighton S A, Watkins P B, Kremers P, Mendez-Picon G, Parker G A, Guzelian P S. PubMed
Variant Summaries rs12721627, rs12721634, rs2740574, rs4986907, rs4986908, rs4986909, rs4986910, rs4986913, rs4987161
Haplotype Summaries CYP3A4*1A, CYP3A4*1B (CYP3A4-V) , CYP3A4*1C, CYP3A4*1D, CYP3A4*1E, CYP3A4*1F, CYP3A4*1G, CYP3A4*1H, CYP3A4*1J , CYP3A4*1K, CYP3A4*1L, CYP3A4*1M, CYP3A4*1N, CYP3A4*1P, CYP3A4*1Q, CYP3A4*1R, CYP3A4*1S, CYP3A4*1T, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15A, CYP3A4*15B, CYP3A4*16A, CYP3A4*16B, CYP3A4*17, CYP3A4*18A, CYP3A4*18B, CYP3A4*19, CYP3A4*20
Drugs
Drug Substrate (72)
alfentanil, alprazolam, amlodipine, aprepitant, aripiprazole, astemizole, atorvastatin, buspirone, caffeine, cerivastatin, chlorpheniramine, cilostazol, cisapride, clarithromycin, cocaine, codeine, cyclosporine, dapsone, dextromethorphan, diazepam, diltiazem, docetaxel, domperidone, eplerenone, erythromycin, estradiol, felodipine, fentanyl, finasteride, haloperidol, hydrocortisone, imatinib, indinavir, irinotecan, lercanidipine, levomethadyl acetate, lidocaine, lovastatin, methadone, midazolam, nateglinide, nelfinavir, nifedipine, nisoldipine, nitrendipine, ondansetron, paclitaxel, pimozide, progesterone, propranolol, quetiapine, quinidine, quinine, risperidone, ritonavir, salmeterol, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tamoxifen, telithromycin, terfenadine, testosterone, trazodone, triazolam, verapamil, vincristine, zaleplon, ziprasidone, zolpidem
Diseases
Pathways

Haplotype Overview

Haplotypes are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database (version 3/5/2012 plus changes up to 11/25/2013; PharmGKB update 3/12/2014). The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence AF280107.1. Note that the nucleotide positions from the Human Cytochrome P450 (CYP) Allele Nomenclature Database do not directly match the given NCBI reference sequence. For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.

PharmGKB has added some alleles below (e.g. the row for *1), inserted for star alleles with subgroups (e.g. A, B etc). These rows reflect only the defining SNP for the star allele to accommodate how the star allele is referred to in the literature.

Source: PharmGKB

Haplotypes for CYP3A4

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
    Stylized diagram showing acetaminophen metabolism and transport in the liver.
  1. Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
    Nateglinide metabolism and transport in liver cell
  1. Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics
    Repaglinide metabolism and transport in a liver cell.
  1. Artemisinin and Derivatives Pathway, Pharmacokinetics
    Genes involved in the pharmacokinetics of the antimalarial drugs artemisinin, arsenate, artemether, and arteether.
  1. Atomoxetine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of atomoxetine.
  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Benzodiazepine Pathway, Pharmacokinetics
    Diagrammatic representation of the metabolism of different benzodiazepine drugs by candidate genes.
  1. Caffeine Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
  1. Celecoxib Pathway, Pharmacokinetics
    Schematic representation of celecoxib metabolism in human liver cell.
  1. Citalopram Pathway, Pharmacokinetics
    Pharmacokinetics of the selective serotonin reuptake inhibitor citalopram.
  1. Clomipramine Pathway, Pharmacokinetics
    Schematic representation of clomipramine metabolism in human liver.
  1. Clopidogrel Pathway, Pharmacokinetics
    Representation of genes involved in metabolism of clopidogrel.
  1. Codeine and Morphine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in metabolism of codeine and morphine.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Doxepin Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of the tricyclic doxepin.
  1. Efavirenz Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of efavirenz metabolism and mechanism of action against HIV.
  1. Erlotinib Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.
  1. Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
    Etoposide cellular disposition and effects.
  1. Fluoxetine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of fluoxetine.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Gefitinib Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the transportation and metabolism of gefitinib.
  1. Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
    Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.
  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Ifosfamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of ifosfamide.
  1. Imipramine/Desipramine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of the tricyclic antidepressants imipramine and desipramine.
  1. Irinotecan Pathway, Pharmacokinetics
    Model human liver cell showing blood, bile and intestinal compartments, indicating tissue specific involvement of genes in the irinotecan pathway.
  1. Ivacaftor pathway, pharmacokinetics/pharmacodynamics
    Stylized liver cell showing genes involved in the metabolism of ivacaftor, and stylized epithelial cell showing the potentiation of CFTR gating with ivacaftor treatment alone and with ivacftor plus lumacaftor treatment.
  1. Losartan Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of losartan.
  1. Macrolide Antibiotic Pathway, Pharmacokinetics/Pharmacodynamics
    Stylized depiction of the genes involved in the transport, metabolism and mechanism of action of the macrolide antibiotics erythromycin, clarithromycin, and azithromycin.
  1. Metformin Pathway, Pharmacodynamics
    Simplified diagram of mechanism of action of metformin.
  1. Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of mycophenolic acid metabolism.
  1. Nevirapine Pathway, Pharmacokinetics
    Representation of candidate genes involved in biotransformation of nevirapine and its mechanism of action in an infected liver cell.
  1. Paroxetine Pathway, Pharmacokinetics
    Genes involved in the metabolism of paroxetine and in the mechanism of action.
  1. Pazopanib Pathway, Pharmacokinetics
    Stylized representation of pazopanib transport and metabolism in the liver.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. Proton Pump Inhibitor Pathway, Pharmacokinetics
    Omeprazole metabolism in the liver.
  1. Sirolimus Pathway, Pharmacokinetics/Pharmacodynamics
    Representation of sirolimus pharmacokinetics and pharmacodynamics
  1. Sorafenib Pharmacokinetics
    Schematic representation of sorafenib metabolism in human liver cell.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Tacrolimus/Cyclosporine Pathway, Pharmacokinetics
    Schematic representation of tacrolimus and cyclosporine metabolism
  1. Tamoxifen Pathway, Pharmacokinetics
    Diagram showing candidate genes for tamoxifen metabolism in the liver.
  1. Taxane Pathway, Pharmacokinetics
    Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs.
  1. Theophylline Pathway, Pharmacokinetics
    Schematic representation of theophylline metabolism in human liver.
  1. Tramadol Pharmacokinetics
    Schematic representation of tramadol metabolism in human liver cell.
  1. Venlafaxine Pathway, Pharmacokinetics
    Stylized cells depicting the metabolism and mechanism of action of venlafaxine.
  1. Vinka Alkaloid Pathway, Pharmacokinetics
    Representation of the genes involved in the metabolism, transport, and downstream effects of the vinca alkaloid vincristine.
  1. Voriconazole Pathway, Pharmacokinetics
    Pathway describing the metabolism of voriconazole
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.
  1. Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
    Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MIR27A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
VDR

Curated Information ?

Evidence Drug
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abiraterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
acenocoumarol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
acetaminophen
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alectinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
alfentanil
alprazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ambrisentan
amlodipine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
aprepitant
aripiprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aripiprazole lauroxil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
arteether
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
artemether
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
artemisinin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
astemizole
No Dosing Guideline available DL CA VA No VIP available No VIP available
atazanavir
atorvastatin
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
axitinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
belinostat
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bevacizumab
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
boceprevir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bosutinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
brentuximab vedotin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
brexpiprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
buspirone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabazitaxel
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabozantinib
caffeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
capecitabine
carbamazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
celecoxib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ceritinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cerivastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cevimeline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
chlorpheniramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cilostazol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cisapride
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
cisplatin
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available PW
citalopram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
clarithromycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clobazam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
clomipramine
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
clopidogrel
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clozapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cocaine
codeine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
cyclophosphamide
cyclosporine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dabrafenib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
daclatasvir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
dapsone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
darifenacin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
darunavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
desipramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexlansoprazole
dextromethorphan
diazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
diltiazem
docetaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
domperidone
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
donepezil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
doxepin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
doxorubicin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dronedarone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
drospirenone
efavirenz
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eliglustat
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eltrombopag
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
emtricitabine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
enzalutamide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epclusa
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
epirubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
eplerenone
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available PW
erlotinib
erythromycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
escitalopram
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
esomeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
estradiol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethinyl estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
etoposide
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
everolimus
No Dosing Guideline available DL CA VA No VIP available No VIP available
exemestane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
felodipine
fentanyl
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fesoterodine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
finasteride
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flibanserin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
flunitrazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluorouracil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
fluoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluticasone propionate
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
fluvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluvoxamine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fosamprenavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fulvestrant
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
galantamine
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available PW
gefitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gemcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
haloperidol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hydrocortisone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ibuprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ifosfamide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
iloperidone
imatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
imipramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indacaterol
indinavir
irinotecan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivabradine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor / lumacaftor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lacosamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lamivudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lamotrigine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lapatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
lercanidipine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
letrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
levomethadyl acetate
lidocaine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lomitapide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lopinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
losartan
lovastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maraviroc
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
marinol
methadone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
methotrexate
midazolam
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
modafinil
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
mycophenolate mofetil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
mycophenolic acid
nateglinide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nefazodone
nelfinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
nevirapine
nifedipine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nilotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
nisoldipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
nitrendipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
olanzapine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
olaparib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
omeprazole
ondansetron
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
oxaliplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
oxazepam
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxcarbazepine
paclitaxel
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
palonosetron
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
pantoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
paroxetine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pazopanib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
phenprocoumon
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
phenytoin
pimozide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ponatinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
posaconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prasugrel
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prilocaine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
primidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
progesterone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propafenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
quetiapine
quinidine
quinine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ranolazine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
regorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
repaglinide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
rilpivirine
risperidone
ritonavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rosuvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rucaparib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ruxolitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
salmeterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
saquinavir
sildenafil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
simeprevir
simvastatin
sirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
sorafenib
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
sunitinib
tacrolimus
tamoxifen
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tamsulosin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
technivie
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telaprevir
telithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
temazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
teniposide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tenofovir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
terfenadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
testosterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
theophylline
No Dosing Guideline available DL CA VA No VIP available No VIP available
ticagrelor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tiotropium
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tipifarnib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tipranavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolterodine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available PW
tramadol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trametinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
trastuzumab
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab emtansine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
trazodone
triazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
valproic acid
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vandetanib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vardenafil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vemurafenib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
venetoclax
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available PW
venlafaxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
verapamil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Viekira Pak
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vilazodone
vincristine
No Dosing Guideline available DL CA VA No VIP available No VIP available
voriconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vortioxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
warfarin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
zaleplon
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
zidovudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
ziprasidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
zolpidem
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zonisamide

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
acute cellular rejection
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alzheimer Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asthma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bioavailability
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Carcinoma, Small Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carotid Artery Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Chronic Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
contralateral breast cancer
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dementia
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder, Major
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
dry mouth
Endometrial Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exanthema
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart valve replacement
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Helicobacter Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Hepatitis C, Chronic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Heroin Dependence
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hot Flashes
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hyperlipidemias
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
infusion related reaction
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
liver transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lung transplantation
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neurotoxicity Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Opioid-Related Disorders
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Organ Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Osteosarcoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Ovarian Failure, Premature
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ovarian Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Peripheral Nervous System Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
progression-free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Prostatic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Psychotic Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Stomach Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Substance-Related Disorders
therapy-related acute myeloid leukemia (t-ML)
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
transplant rejection
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
treatment modification

Publications related to CYP3A4: 585

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Pharmacokinetic Interaction between Ivacaftor and Ritonavir in Healthy Volunteers. British journal of clinical pharmacology. 2017. Liddy Anne Marie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin. Clinical and translational science. 2017. Kitzmiller J P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms of drug-drug interaction between rifampicin and fusidic acid. British journal of clinical pharmacology. 2017. Bel Florianne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole. Clinical pharmacology and therapeutics. 2017. Walsh T J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Auto-inhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. British journal of clinical pharmacology. 2017. Hohmann Nicolas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dapsone-induced agranulocytosis - possible involvement of low activity N-acetyltransferase 2. Fundamental & clinical pharmacology. 2017. Potočnjak Ines, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing. Pharmacogenomics. 2017. Haga Susanne B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4 induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients with CYP24A1 Mutations. The Journal of clinical endocrinology and metabolism. 2017. Hawkes Colin Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. The primary care companion for CNS disorders. 2017. Olson Marilyn C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Basic & clinical pharmacology & toxicology. 2017. Karaca R Ozgur, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of voriconazole: CYP2C19 but also CYP3A4 need to be genotyped. Clinical pharmacology and therapeutics. 2017. Gautier-Veyret Elodie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. Drugs in R&D. 2017. Madsen Mads Juul, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients. Acta pharmacologica Sinica. 2017. Liu Mou-Ze, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. British journal of clinical pharmacology. 2017. Calvo Pier Luigi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clinical pharmacokinetics. 2017. Andreu Franc, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. Medicine. 2017. Liu Rui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenetics and genomics. 2017. Fohner Alison E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Correlations between the enantio- and regio-selective metabolisms of warfarin. Pharmacogenomics. 2017. Takahashi Harumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacological reports : PR. 2017. López-García Miguel A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects. Biological & pharmaceutical bulletin. 2017. Li Mupeng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. The pharmacogenomics journal. 2016. Meulendijks D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol. American journal of surgery. 2016. Senagore Anthony J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. Omics : a journal of integrative biology. 2016. De Andrés Fernando, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals. Antimicrobial agents and chemotherapy. 2016. Aouri Manel, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. Transplantation. 2016. Debette-Gratien Marilyne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome and sulfotransferase gene variation in north African populations. Pharmacogenomics. 2016. Fernández-Santander Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Pharmacogenomics. 2016. Tang Qian-Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. The pharmacogenomics journal. 2016. Hertz D L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology. 2016. Tverdohleb Tatiana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical research. 2016. Gonzalez-Covarrubias Vanessa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical pharmacokinetics. 2016. Csajka Chantal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clinical pharmacology and therapeutics. 2016. Yang Wenjian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clinical transplantation. 2016. Deininger Kimberly M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. European journal of clinical pharmacology. 2016. Atiq Ferdows, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. European journal of clinical pharmacology. 2016. Song Ivy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications. Pharmacogenetics and genomics. 2016. Creemer Olivia J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients. Iranian journal of kidney diseases. 2016. Yousef Al-Motassem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. Pharmacogenomics. 2016. Mpeta Bafokeng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2016. Hirose Takashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic or -epigenomic biomarkers in drug treatment - two sides of the same medal?. Clinical pharmacology and therapeutics. 2016. Ingelman-Sundberg Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2016. González A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016. Hocum Brian Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The impact of genetic factors on response to glucocorticoids therapy in IBD. Scandinavian journal of gastroenterology. 2016. Gabryel Marcin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. The pharmacogenomics journal. 2016. Diekstra M H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clinical pharmacokinetics. 2015. Vandenberghe Frederik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Yamaura Yoshiyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Tracy Timothy S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. European journal of clinical pharmacology. 2015. Xu Huiping, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and therapy. 2016. Kus Tulay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
4beta-Hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?. British journal of clinical pharmacology. 2015. Gjestad Caroline, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy research. 2015. Wang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics. 2015. Aouam Karim, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clinical pharmacokinetics. 2015. Gibbons Jacqueline A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In Vitro Kinetic Characterization of Axitinib Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Zientek Michael A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. European journal of clinical pharmacology. 2015. Moes D J A R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenetics and genomics. 2015. Wang Danxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. British journal of clinical pharmacology. 2015. Monostory Katalin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. British journal of clinical pharmacology. 2015. Wiesinger Herbert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Hagleitner Melanie M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European heart journal. 2015. Varenhorst Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer. 2015. Kobayashi Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. International journal of clinical pharmacology and therapeutics. 2015. Zhang Jing-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Journal of cardiovascular pharmacology. 2015. Luzum Jasmine A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015. Li Jia-Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
4beta-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. British journal of clinical pharmacology. 2015. de Graan Anne-Joy M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing hematocrit. British journal of clinical pharmacology. 2015. de Jonge Hylke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics. 2015. Pulk Rebecca A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic & clinical pharmacology & toxicology. 2015. Markert Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2015. Tao Xing-Ru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenetics and genomics. 2015. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2015. He H-R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics. 2015. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. Cancer chemotherapy and pharmacology. 2015. Hamberg P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular cancer therapeutics. 2015. Kendra Kari L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015. Pallet N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of glinides. Pharmacogenomics. 2015. Chen Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. British journal of clinical pharmacology. 2014. Carls Alexandra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Frontiers in genetics. 2015. Swart Marelize, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation. International journal of clinical and experimental medicine. 2015. Zhu Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. International journal of clinical and experimental pathology. 2015. He Yongjun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ibuprofen pathways. Pharmacogenetics and genomics. 2014. Mazaleuskaya Liudmila L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hsa-miR-27a is involved in the regulation of CYP3A4 expression in human livers from Chinese Han population. Pharmacogenomics. 2015. Shi Ye, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. Pharmacogenomics. 2015. Ferraresso Mariano, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015. Helton Sarah G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. PloS one. 2015. Shi Wei-Long, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica; the fate of foreign compounds in biological systems. 2015. House Larry, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Apellániz-Ruiz Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PPARA gene and phenprocoumon: a new predictor of response variability. Pharmacogenetics and genomics. 2014. Botton Mariana R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics. 2014. Bosó Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ivacaftor for patients with cystic fibrosis. Expert review of respiratory medicine. 2014. Wainwright Claire E. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenetics and genomics. 2014. Kuypers Dirk R J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. The pharmacogenomics journal. 2014. de Jonge H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. British journal of clinical pharmacology. 2014. ter Heine Rob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary hydrocodone and metabolite distributions in pain patients. Journal of analytical toxicology. 2014. Barakat Neveen H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Molecular biology reports. 2014. Sharaki Ola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. Pharmacogenetics and genomics. 2014. Abubakar Murtala B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia. The pharmacogenomics journal. 2014. Gézsi A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Therapeutic drug monitoring. 2014. Bruckmueller Henrike, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. European journal of clinical pharmacology. 2014. Dutreix Catherine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. Journal of clinical pharmacology. 2014. Robertson Sarah M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenetics and genomics. 2014. Kitzmiller Joseph P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics. 2014. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. British journal of clinical pharmacology. 2014. Noetzli Muriel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clinical pharmacology and therapeutics. 2014. Diekstra M H M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clinical pharmacology and therapeutics. 2014. Tsamandouras N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug metabolism and disposition: the biological fate of chemicals. 2014. Filppula Anne M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. Breast cancer research and treatment. 2014. Baxter Simon D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene. 2014. Tulsyan Sonam, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics. 2014. Guy-Viterbo Vanessa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clinical transplantation. 2014. Schoeppler Kelly E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genetics in medicine : official journal of the American College of Medical Genetics. 2014. Canestaro William J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. Basic & clinical pharmacology & toxicology. 2014. Botton Mariana R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. British journal of clinical pharmacology. 2014. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of platelet inhibitor treatment. British journal of clinical pharmacology. 2014. Trenk Dietmar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients. International journal of clinical pharmacology and therapeutics. 2014. Xin Hua-Wen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. The Journal of antimicrobial chemotherapy. 2014. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Grapefruit juice inhibits the metabolic activation of clopidogrel. Clinical pharmacology and therapeutics. 2014. Holmberg M T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990). 2014. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. European journal of clinical pharmacology. 2014. Lunde Ingrid, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2014. Lowenberg Daniella, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014. Kurzawski Mateusz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. The Journal of infectious diseases. 2014. Bertrand Julie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults. Drug metabolism and pharmacokinetics. 2014. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and genomics. 2014. Barratt Daniel T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. CPT: pharmacometrics & systems pharmacology. 2014. Moes D J A R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. Clinical chemistry. 2013. Woillard Jean-Baptiste, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance. Frontiers in genetics. 2014. Swart Marelize, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial. Journal of atherosclerosis and thrombosis. 2014. Suh Jung-Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014. Zhu Xu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring the distribution of genetic markers of pharmacogenomics relevance in brazilian and mexican populations. PloS one. 2014. Bonifaz-Peña Vania, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PloS one. 2014. Li Chuan-Jiang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions. 2013. Viviani Anselmi Chiara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification and characterization of a defect CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clinical pharmacology and therapeutics. 2013. Werk Anneke Nina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines. Therapeutic drug monitoring. 2013. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen. Drug metabolism and disposition: the biological fate of chemicals. 2013. Liu Jinzhong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study. Cancer causes & control : CCC. 2013. Brooks Jennifer D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients. Clinical pharmacology and therapeutics. 2013. Santoro A B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics. 2013. Gijsen Violette Mgj, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. British journal of clinical pharmacology. 2013. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. de Graan Anne-Joy M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. European journal of clinical pharmacology. 2013. Ciccacci Cinzia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. International journal of clinical pharmacology and therapeutics. 2013. Li Dan-ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. Journal of clinical psychopharmacology. 2013. Choong Eva, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenetics and genomics. 2013. Tavira Beatriz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenetics and genomics. 2013. Fohner Alison, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on CYP3A-Mediated Drug-Drug Interactions. Drug metabolism and disposition: the biological fate of chemicals. 2013. Shirasaka Yoshiyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Human psychopharmacology. 2013. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria pharmacogenomics: return to the future. Pharmacogenomics. 2013. Gil Jp. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert opinion on drug metabolism & toxicology. 2013. Agúndez José A G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics. 2013. Spraggs Colin F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Therapeutic drug monitoring. 2013. Noetzli Muriel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. Clinical pharmacology and therapeutics. 2013. Ulvestad M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug metabolism and disposition: the biological fate of chemicals. 2013. Dragovic Sanja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the effect of SNPs in CYP3A4 and CYP4F2 on the stable phenprocoumon and acenocoumarol maintenance dose. Journal of thrombosis and haemostasis : JTH. 2013. van Schie Rianne M F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARalpha). Molecular pharmacology. 2013. Thomas Maria, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenetics and genomics. 2013. Zuo Xiao-Cong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013. Hertz D L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013. Angelini Sabrina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. Journal of pharmaceutical sciences. 2013. Sadee Wolfgang. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug metabolism and drug interactions. 2013. Kitzmiller Joseph Paul, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amlodipine - Not a Significant Contributor to Clopidogrel Non-Response?. Heart (British Cardiac Society). 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013. Puranik Yogita Ghodke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics. 2013. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 2013. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of clinical response to risperidone. Pharmacogenomics. 2013. Llerena Adrián, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics. 2013. Hassan Moustapha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control. The Journal of pediatrics. 2013. Stockmann Chris, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A5 Gene Variation Influences Cyclosporine A Metabolite Formation and Renal Cyclosporine Disposition. Transplantation. 2013. Zheng Songmao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of Cytochrome P450 (CYP) 3A4*1G Polymorphism on the Pharmacokinetics of Tacrolimus, Probability of Acute Cellular Rejection, and mRNA Expression Level of CYP3A5 Rather than CYP3A4 in Living-Donor Liver Transplant Patients. Biological & pharmaceutical bulletin. 2013. Uesugi Miwa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 3A4*22, PPAR-alpha, and ARNT polymorphisms and clopidogrel response. Clinical pharmacology : advances and applications. 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012. Sharma Anant, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D(3) through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human genetic variation of CYP450 superfamily: analysis of functional diversity in worldwide populations. Pharmacogenomics. 2012. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenetics and genomics. 2012. Hu Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicology and applied pharmacology. 2012. Poulton Emma Jane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS research and human retroviruses. 2012. Kile Deidre A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic contribution to variable human CYP3A-mediated metabolism. Advanced drug delivery reviews. 2012. Lamba Jatinder K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4 and CYP2C19 genetic polymorphisms and zolpidem metabolism in the Chinese Han population: A pilot study. Forensic science international. 2012. Shen Min, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenetics and genomics. 2012. Wu Hongyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interplay between Vitamin D and the Drug Metabolizing Enzyme CYP3A4. The Journal of steroid biochemistry and molecular biology. 2012. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1alpha,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells. Biochemical pharmacology. 2012. Zheng Xi Emily, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS computational biology. 2012. Duke Jon D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: phenytoin pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. European journal of clinical pharmacology. 2012. Brennan Meghan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenetics and genomics. 2012. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast cancer research and treatment. 2012. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Molecular pharmacology. 2012. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clinical pharmacology and therapeutics. 2012. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pazopanib for the treatment of metastatic renal cell carcinoma. Clinical therapeutics. 2012. Pick Amy M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British journal of clinical pharmacology. 2012. Lane Steven, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: caffeine pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenetics and genomics. 2012. Birdwell Kelly A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012. Brown Kevin C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011. Dandara Collet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation. 2011. Sam Wai-Johnn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer chemotherapy and pharmacology. 2011. Guilhaumou Romain, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clinical chemistry. 2011. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. The Journal of pharmacology and experimental therapeutics. 2011. Abell Lynn M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2011. Jornil Jakob, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011. Chen Chia-Hui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica; the fate of foreign compounds in biological systems. 2011. Seo Kyung-Ah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clinical pharmacokinetics. 2011. Di Gion Paola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clinical pharmacology and therapeutics. 2011. de Jonge H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study. Pharmacogenetics and genomics. 2011. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011. de Jonge Hylke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. The Journal of clinical psychiatry. 2011. Laughren Thomas P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Irvin William J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide. The breast journal. 2011. Wessels Alette M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics. 2011. Miura Masatomo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011. Müller Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical pharmacology and therapeutics. 2011. Scott S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clinical pharmacology and therapeutics. 2011. Schmitt C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism. Clinical pharmacology and therapeutics. 2011. Franke R M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. European journal of clinical pharmacology. 2011. Russo Roberta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011. Keisner Sidney V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug metabolism and disposition: the biological fate of chemicals. 2011. Lindh Jonatan D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011. Jacobson Pamala A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug metabolism and drug interactions. 2011. Cousins Darren, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European heart journal. 2010. Harmsze Ankie M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. Journal of acquired immune deficiency syndromes (1999). 2010. Svärd Jenny, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological reports : PR. 2011. Baer-Dubowska Wanda, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clinical pharmacology and therapeutics. 2010. Goh B C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010. Becker Mara L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. The Annals of pharmacotherapy. 2010. Smith Nicola F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. The Journal of molecular diagnostics : JMD. 2010. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population Pharmacokinetic modelling of the association between 63396C->T Pregnane-X-Receptor (PXR) polymorphism and unboosted atazanavir clearance. Antimicrobial agents and chemotherapy. 2010. Schipani Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clinical pharmacology and therapeutics. 2010. Templeton I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Current drug metabolism. 2010. Ancrenaz V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. JAMA : the journal of the American Medical Association. 2010. Fuster Valentin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenetics and genomics. 2010. Agrawal Vishal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach. Pharmacogenomics. 2010. Pallet Nicolas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010. Wang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clinical pharmacology and therapeutics. 2010. Tapaninen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In Vitro P450-Mediated Metabolism of Exemestane. Drug metabolism and disposition: the biological fate of chemicals. 2010. Kamdem Landry K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clinical pharmacology and therapeutics. 2010. Karonen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Therapeutic drug monitoring. 2010. Kuypers Dirk R J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and sterility. 2010. Su H Irene, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clopidogrel pathway. Pharmacogenetics and genomics. 2010. Sangkuhl Katrin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Oswald S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. The pharmacogenomics journal. 2010. de Vos A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. The pharmacogenomics journal. 2010. Bonelli P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Use of pharmacogenetics to optimize immunosuppressive therapy. Therapeutic drug monitoring. 2010. Macphee Iain A M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharmaceutics & drug disposition. 2010. Zhou Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2010. Oliver Paloma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug metabolism and disposition: the biological fate of chemicals. 2010. Kazui Miho, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Journal of clinical pharmacology. 2010. Farid Nagy A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiology and drug safety. 2010. Becker Matthijs L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clinical pharmacokinetics. 2010. Staatz Christine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The pharmacogenomics journal. 2010. Wang D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clinical pharmacokinetics. 2010. Staatz Christine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. The pharmacogenomics journal. 2010. Leskelä S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Individualizing dosing of irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010. Ratain Mark J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism. European journal of clinical pharmacology. 2010. Gorny Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Human genetics. 2010. Rodriguez-Antona Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. American journal of nephrology. 2010. Bhatnagar Vibha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochemical pharmacology. 2009. Zharikova Olga L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR. 2010. Gor Priya P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clinical pharmacology and therapeutics. 2009. Zhao W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clinical pharmacology and therapeutics. 2009. Willmann S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause (New York, N.Y.). 2010. Rebbeck Timothy R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxane Pathway. Pharmacogenetics and genomics. 2009. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clinical pharmacology and therapeutics. 2009. Schwartz J B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys. Drug metabolism and disposition: the biological fate of chemicals. 2009. Ogasawara Akihito, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. Journal of the American Society of Nephrology : JASN. 2009. Naesens Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicology and applied pharmacology. 2009. Ganesan Shobana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 2009. Murai K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. Clinical pharmacology and therapeutics. 2009. Braun F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Macrolide-induced digoxin toxicity: a population-based study. Clinical pharmacology and therapeutics. 2009. Gomes T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. Journal of human genetics. 2009. Cha Pei-Chieng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. Journal of the American College of Cardiology. 2009. Rossi Joseph S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. The pharmacogenomics journal. 2009. Miao J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Current clinical pharmacology. 2009. Srinivas Nuggehally R. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal cancer research : GCR. 2009. Yalçin Suayib. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. Marín Francisco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics. 2009. Oliveira Elisabete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Voso Maria Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism of loratadine and further characterization of its in vitro metabolites. Drug metabolism letters. 2009. Ghosal Anima, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. European journal of clinical pharmacology. 2009. Vevelstad M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. European journal of clinical pharmacology. 2009. Bertrand Julie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics. 2009. Gomez Alvin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of anxiolytic drugs. Journal of neural transmission (Vienna, Austria : 1996). 2009. Tiwari Arun K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009. Willrich Maria Alice Vieira, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of antiplatelet drug resistance. Clinical genetics. 2009. Feher G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clinical pharmacology and therapeutics. 2009. Arab-Alameddine M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European heart journal. 2009. Varenhorst Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European heart journal. 2009. Wallentin Lars. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV medicine. 2009. Mahungu Tw, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart and vessels. 2009. Brackbill Marcia L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. The American journal of cardiology. 2009. Lee Jung Myung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacoepigenetics: its role in interindividual differences in drug response. Clinical pharmacology and therapeutics. 2009. Gomez A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Therapeutic drug monitoring. 2009. Press Rogier R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clinical pharmacology and therapeutics. 2009. Zhang Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clinical pharmacology and therapeutics. 2009. Kang Y S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic drug metabolism in anaesthesia. Current drug metabolism. 2009. Restrepo Juan G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert opinion on drug metabolism & toxicology. 2009. Phan Viet Hong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics. 2009. Mehlotra Rajeev K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic pathway analysis of docetaxel elimination. Clinical pharmacology and therapeutics. 2009. Baker S D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica; the fate of foreign compounds in biological systems. 2009. Maekawa K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. British journal of clinical pharmacology. 2009. Ekhart Corine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 2009. Laine J E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009. Keating Gillian M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin. Patient preference and adherence. 2009. Bachmann Gloria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical therapeutics. 2008. Deremer David L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug metabolism and disposition: the biological fate of chemicals. 2008. Yeung Eugene Y H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug metabolism and disposition: the biological fate of chemicals. 2008. Zhang Jiang-Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Benzodiazepine metabolism: an analytical perspective. Current drug metabolism. 2008. Mandrioli Roberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clinical pharmacology and therapeutics. 2008. Myrand S P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis. European journal of clinical pharmacology. 2008. Luoma Pauli V. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008. Madadi Parvaz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transplant international : official journal of the European Society for Organ Transplantation. 2008. Grinyó Josep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochemical pharmacology. 2008. Kot Marta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Yasuda Kazuto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Pearce Robin E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clinical pharmacology and therapeutics. 2008. Ufer M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clinical pharmacology and therapeutics. 2008. Magnusson M O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics. 2008. Kohlrausch Fabiana B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clinical pharmacology and therapeutics. 2008. Muruganandan S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenetics and genomics. 2008. Kamdem Landry K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenetics and genomics. 2008. Ekhart Corine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clinical pharmacology and therapeutics. 2008. Kanebratt K P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clinical pharmacology and therapeutics. 2008. Hynninen V-V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiretroviral agents. Current opinion in HIV and AIDS. 2008. Owen Andrew, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug metabolism and disposition: the biological fate of chemicals. 2008. Lu Chuang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug metabolism and disposition: the biological fate of chemicals. 2008. Sane Rucha S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. European journal of clinical pharmacology. 2008. Gao Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical use and pharmacological properties of selective COX-2 inhibitors. European journal of clinical pharmacology. 2008. Shi Shaojun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. European journal of clinical pharmacology. 2008. Ohlsson Rosenborg Staffan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2008. Takahashi Makoto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. Journal of the American College of Cardiology. 2008. Siller-Matula Jolanta M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008. Geisler Tobias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacology & therapeutics. 2008. Hines Ronald N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. The American journal of cardiology. 2008. Frere Corinne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Rudin Charles M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene ex